PRAP1

Summary

PRAP1 (proline rich acidic protein 1, HGNC:23304) is a protein-coding gene on chromosome 10q26.3, encoding Proline-rich acidic protein 1 (Q96NZ9). Lipid-binding protein which promotes lipid absorption by facilitating MTTP-mediated lipid transfer (mainly triglycerides and phospholipids) and MTTP-mediated apoB lipoprotein assembly and secretion.

Predicted to enable triglyceride binding activity. Involved in DNA damage response, signal transduction by p53 class mediator; deactivation of mitotic spindle assembly checkpoint; and negative regulation of apoptotic process. Predicted to be located in endoplasmic reticulum and extracellular region.

Source: NCBI Gene 118471 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 28 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_145202

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:23304
Approved symbol	PRAP1
Name	proline rich acidic protein 1
Location	10q26.3
Locus type	gene with protein product
Status	Approved
Aliases	UPA
Ensembl gene	ENSG00000165828
Ensembl biotype	protein_coding
OMIM	609776
Entrez	118471

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 7 protein_coding

ENST00000433452, ENST00000463201, ENST00000863040, ENST00000863041, ENST00000863042, ENST00000863043, ENST00000863044

RefSeq mRNA: 2 — MANE Select: NM_145202 NM_001145201, NM_145202

CCDS: CCDS44498, CCDS7679

Canonical transcript exons

ENST00000433452 — 5 exons

Exon	Start	End
ENSE00001185450	133352247	133352683
ENSE00001893257	133347373	133347425
ENSE00003791960	133350095	133350161
ENSE00003797617	133352007	133352140
ENSE00003800860	133351381	133351433

Expression profiles

Bgee: expression breadth ubiquitous, 128 present calls, max score 99.70.

FANTOM5 (CAGE): breadth broad, TPM avg 4.8619 / max 1517.2837, expressed in 230 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
107791	4.0799	205
107790	0.7820	95

Top tissues by expression

133 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
duodenum	UBERON:0002114	99.70	gold quality
right lobe of liver	UBERON:0001114	99.27	gold quality
liver	UBERON:0002107	98.95	gold quality
mucosa of transverse colon	UBERON:0004991	97.73	gold quality
adult mammalian kidney	UBERON:0000082	95.32	gold quality
small intestine Peyer’s patch	UBERON:0003454	94.53	gold quality
small intestine	UBERON:0002108	94.09	gold quality
rectum	UBERON:0001052	89.10	gold quality
transverse colon	UBERON:0001157	87.55	gold quality
kidney	UBERON:0002113	87.12	gold quality
right testis	UBERON:0004534	83.56	gold quality
left testis	UBERON:0004533	82.50	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.23	silver quality
testis	UBERON:0000473	81.63	gold quality
tibial nerve	UBERON:0001323	81.52	gold quality
intestine	UBERON:0000160	79.98	gold quality
cortex of kidney	UBERON:0001225	77.16	gold quality
colon	UBERON:0001155	74.85	gold quality
metanephros cortex	UBERON:0010533	73.79	gold quality
vermiform appendix	UBERON:0001154	69.90	gold quality
gall bladder	UBERON:0002110	67.68	gold quality
colonic epithelium	UBERON:0000397	64.83	silver quality
monocyte	CL:0000576	64.30	gold quality
right uterine tube	UBERON:0001302	63.78	gold quality
smooth muscle tissue	UBERON:0001135	63.60	gold quality
mucosa of stomach	UBERON:0001199	63.42	gold quality
leukocyte	CL:0000738	62.41	gold quality
ovary	UBERON:0000992	61.08	gold quality
granulocyte	CL:0000094	61.02	gold quality
right ovary	UBERON:0002118	60.96	gold quality

Single-cell (SCXA)

Detected in 10 experiment(s), a significant marker in 8.

Experiment	Marker?	Max mean expression
E-GEOD-125970	yes	12140.97
E-CURD-46	yes	8356.12
E-CURD-122	yes	3765.02
E-MTAB-9906	yes	2259.23
E-MTAB-8410	yes	1370.22
E-CURD-98	yes	917.48
E-HCAD-9	yes	55.94
E-ANND-3	yes	24.04
E-MTAB-3929	no	330.40
E-MTAB-6379	no	1.34

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): TP53

miRNA regulators (miRDB)

8 targeting PRAP1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-548AZ-5P	99.83	69.94	3230
HSA-MIR-548T-5P	99.83	69.91	3220
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-6504-3P	99.17	69.31	2891
HSA-MIR-193B-5P	97.91	65.88	837
HSA-MIR-1234-3P	86.70	58.45	109
HSA-MIR-7107-5P	86.70	59.28	110

Literature-anchored findings (GeneRIF, showing 4)

• Induction of PRAP1 expression by p53 in response to DNA-damaging agents contributes to cancer cell survival. (PMID:23235459)
• PRAP1 is a protein interacting partner of MAD1 and that PRAP1 is able to down-regulate MAD1 and suppress mitotic checkpoint signalling in hepatocellular carcinoma. (PMID:24374861)
• ATF3 and PRAP1 play important roles in cisplatin-induced DNA damage repair process. (PMID:29886035)
• Proline-Rich Acidic Protein 1 (PRAP1) Protects the Gastrointestinal Epithelium From Irradiation-Induced Apoptosis. (PMID:32629119)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Prap1	ENSMUSG00000025467
rattus_norvegicus	Prap1	ENSRNOG00000018446

Protein

Protein identifiers

Proline-rich acidic protein 1 — Q96NZ9 (reviewed: Q96NZ9)

Alternative names: Epididymis tissue protein Li 178, Uterine-specific proline-rich acidic protein

All UniProt accessions (2): A6XND8, Q96NZ9

UniProt curated annotations — full annotation on UniProt →

Function. Lipid-binding protein which promotes lipid absorption by facilitating MTTP-mediated lipid transfer (mainly triglycerides and phospholipids) and MTTP-mediated apoB lipoprotein assembly and secretion. Protects the gastrointestinal epithelium from irradiation-induced apoptosis. May play an important role in maintaining normal growth homeostasis in epithelial cells. Involved in p53/TP53-dependent cell survival after DNA damage. May down-regulate the expression of MAD1L1 and exert a suppressive role in mitotic spindle assembly checkpoint in hepatocellular carcinomas.

Subunit / interactions. Interacts with isoform 1 and isoform 3 of MAD1L1. Interacts with MTTP.

Subcellular location. Secreted. Endoplasmic reticulum.

Tissue specificity. Highly expressed in the intestinal epithelial cells (at protein level). Abundantly expressed in the epithelial cells of the liver, kidney and cervix. Significantly down-regulated in hepatocellular carcinoma and right colon adenocarcinoma compared with the respective adjacent normal tissues. Expressed in epididymis (at protein level).

Induction. Up-regulated by butyrate, trichostatin A and 5’-aza-2’ deoxycytidine. Induced by DNA-damaging agents in a p53/TP53-dependent manner in HepG2 liver cancer cell line and HCT116 colon cancer cell line.

Isoforms (4)

UniProt ID	Names	Canonical?
Q96NZ9-1	1, PRAP	yes
Q96NZ9-2	2
Q96NZ9-3	3, PRAPV1
Q96NZ9-4	4, PRAPV2

RefSeq proteins (2): NP_001138673, NP_660203* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR027922	PRAP	Family

Pfam: PF15314

UniProt features (10 total): sequence variant 4, splice variant 3, signal peptide 1, chain 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96NZ9-F1	61.73	0.02

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 138 (showing top): GOBP_CHROMOSOME_ORGANIZATION, GOBP_DIGESTION, GOBP_POSITIVE_REGULATION_OF_MITOTIC_NUCLEAR_DIVISION, GOBP_REGULATION_OF_CELL_CYCLE_CHECKPOINT, GOBP_RESPONSE_TO_IONIZING_RADIATION, GOBP_REGULATION_OF_NUCLEAR_DIVISION, GOBP_CELL_CYCLE_PHASE_TRANSITION, GOBP_POSITIVE_REGULATION_OF_MITOTIC_CELL_CYCLE, GOBP_CHROMOSOME_SEPARATION, GOBP_POSITIVE_REGULATION_OF_DIGESTIVE_SYSTEM_PROCESS, GOBP_POSITIVE_REGULATION_OF_ORGANELLE_ORGANIZATION, GOBP_POSITIVE_REGULATION_OF_LIPID_TRANSPORT, GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, GOBP_NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATION, GOBP_ORGANOPHOSPHATE_ESTER_TRANSPORT

GO Biological Process (8): DNA damage response (GO:0006974), DNA damage response, signal transduction by p53 class mediator (GO:0030330), negative regulation of apoptotic process (GO:0043066), cellular response to X-ray (GO:0071481), deactivation of mitotic spindle assembly checkpoint (GO:1902426), positive regulation of intestinal lipid absorption (GO:1904731), positive regulation of triglyceride transport (GO:1905885), positive regulation of phospholipid transport (GO:2001140)

GO Molecular Function (3): triglyceride binding (GO:0017129), protein binding (GO:0005515), lipid binding (GO:0008289)

GO Cellular Component (2): extracellular region (GO:0005576), endoplasmic reticulum (GO:0005783)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	2
cellular response to stress	1
signal transduction in response to DNA damage	1
signal transduction by p53 class mediator	1
apoptotic process	1
regulation of apoptotic process	1
negative regulation of programmed cell death	1
response to X-ray	1
cellular response to ionizing radiation	1
negative regulation of mitotic spindle assembly checkpoint signaling	1
intestinal lipid absorption	1
positive regulation of intestinal absorption	1
regulation of intestinal lipid absorption	1
triglyceride transport	1
positive regulation of acylglycerol transport	1
regulation of triglyceride transport	1
phospholipid transport	1
positive regulation of lipid transport	1
regulation of phospholipid transport	1
lipid binding	1
cellular anatomical structure	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

340 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PRAP1	FUOM	A2VDF0	480
PRAP1	RPP40	O75818	471
PRAP1	TMEM184B	Q9Y519	459
PRAP1	LZTS3	O60299	457
PRAP1	NPL	Q9BXD5	405
PRAP1	S4R460	S4R460	402
PRAP1	RPL37A	P12751	401
PRAP1	DSC3	Q14574	381
PRAP1	DSC2	Q02487	375
PRAP1	HDC	P19113	374
PRAP1	DNPH1	O43598	369
PRAP1	CCDC185	Q8N715	355
PRAP1	TRNP1	Q6NT89	335
PRAP1	ZNF511	Q8NB15	321
PRAP1	TMEM54	Q969K7	318

IntAct

51 interactions, top by confidence:

A	B	Type	Score
PRAP1	SGTA	psi-mi:“MI:0915”(physical association)	0.720
UBQLN1	PRAP1	psi-mi:“MI:0915”(physical association)	0.720
SGTA	PRAP1	psi-mi:“MI:0915”(physical association)	0.720
PRAP1	UBQLN1	psi-mi:“MI:0915”(physical association)	0.720
PRAP1	UBQLN1	psi-mi:“MI:0915”(physical association)	0.560
ASPH	PRAP1	psi-mi:“MI:0915”(physical association)	0.560
MEOX2	PRAP1	psi-mi:“MI:0915”(physical association)	0.560
PRAP1	MRFAP1	psi-mi:“MI:0915”(physical association)	0.560
PRAP1	UBQLN2	psi-mi:“MI:0915”(physical association)	0.560
SGTB	PRAP1	psi-mi:“MI:0915”(physical association)	0.560
CEP19	PRAP1	psi-mi:“MI:0915”(physical association)	0.560
HSPA6	PRAP1	psi-mi:“MI:0915”(physical association)	0.560
AHNAK2	PRAP1	psi-mi:“MI:0915”(physical association)	0.560
PRAP1	CD48	psi-mi:“MI:0914”(association)	0.530
PRAP1	HSPA5	psi-mi:“MI:0915”(physical association)	0.400
MEP1B	PRAP1	psi-mi:“MI:0915”(physical association)	0.370
PRAP1	IGHA1	psi-mi:“MI:0914”(association)	0.350
GRB2	PRAP1	psi-mi:“MI:0915”(physical association)	0.000
PRAP1	UBQLN2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (25): PRAP1 (Two-hybrid), PRAP1 (Two-hybrid), LACRT (Affinity Capture-MS), CD48 (Affinity Capture-MS), IGHA1 (Affinity Capture-MS), UBQLN1 (Two-hybrid), CD48 (Affinity Capture-MS), LACRT (Affinity Capture-MS), LTF (Affinity Capture-MS), IGHA1 (Affinity Capture-MS), PRAP1 (Two-hybrid), PRAP1 (Two-hybrid), PRAP1 (Two-hybrid), HSPA6 (Two-hybrid), CEP19 (Two-hybrid)

ESM2 similar proteins: A0JPP4, A2VE23, A4FU49, A8MXV6, E9Q7D5, F1NSM7, P06484, P0C671, P0C7A2, P10636, P10637, P69280, P69282, P69284, P69287, Q0VC16, Q12774, Q196W1, Q1XI13, Q28139, Q2TA21, Q4R729, Q5SRN2, Q5STT6, Q5SWP3, Q5YCV9, Q5YCW1, Q62840, Q63003, Q66666, Q66H38, Q6MG22, Q6UXA7, Q6UXF1, Q71M36, Q8BHE4, Q8BM15, Q8K4L6, Q8N1P7, Q96KW9

Diamond homologs: Q80XD8, Q96NZ9, Q9ES75

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

28 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	24
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

516 predictions. Top by Δscore:

Variant	Effect	Δscore
10:133352238:T:TA	acceptor_gain	1.0000
10:133352245:A:AG	acceptor_gain	1.0000
10:133352245:A:T	acceptor_loss	1.0000
10:133352245:AG:A	acceptor_gain	1.0000
10:133352246:G:GA	acceptor_gain	1.0000
10:133352246:GG:G	acceptor_gain	1.0000
10:133352246:GGC:G	acceptor_gain	1.0000
10:133352246:GGCA:G	acceptor_gain	1.0000
10:133350090:CTCA:C	acceptor_loss	0.9900
10:133350092:CA:C	acceptor_loss	0.9900
10:133350093:A:AG	acceptor_gain	0.9900
10:133350094:G:A	acceptor_loss	0.9900
10:133350094:G:GG	acceptor_gain	0.9900
10:133350094:GGCTC:G	acceptor_gain	0.9900
10:133350157:CCAAG:C	donor_loss	0.9900
10:133350158:CAAGG:C	donor_loss	0.9900
10:133350159:AAG:A	donor_loss	0.9900
10:133350161:GGTA:G	donor_loss	0.9900
10:133350162:G:GA	donor_loss	0.9900
10:133351431:GAA:G	donor_gain	0.9900
10:133351434:G:GG	donor_gain	0.9900
10:133352005:AG:A	acceptor_gain	0.9900
10:133352006:GG:G	acceptor_gain	0.9900
10:133352234:T:TA	acceptor_gain	0.9900
10:133352246:GGCAC:G	acceptor_gain	0.9900
10:133350093:AG:A	acceptor_gain	0.9800
10:133350094:GG:G	acceptor_gain	0.9800
10:133352001:CAGCA:C	acceptor_loss	0.9800
10:133352004:CAGG:C	acceptor_loss	0.9800
10:133352005:A:AG	acceptor_gain	0.9800

AlphaMissense

981 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:133352417:G:C	D145H	0.936
10:133352419:C:A	D145E	0.934
10:133352419:C:G	D145E	0.934
10:133352418:A:C	D145A	0.932
10:133350111:A:C	S9R	0.931
10:133350113:C:A	S9R	0.931
10:133350113:C:G	S9R	0.931
10:133352418:A:T	D145V	0.924
10:133352411:G:C	D143H	0.911
10:133352431:C:A	H149Q	0.907
10:133352431:C:G	H149Q	0.907
10:133352412:A:C	D143A	0.904
10:133352413:C:A	D143E	0.896
10:133352413:C:G	D143E	0.896
10:133352429:C:G	H149D	0.889
10:133352418:A:G	D145G	0.867
10:133352313:A:T	D110V	0.858
10:133352412:A:T	D143V	0.852
10:133352314:C:A	D110E	0.841
10:133352314:C:G	D110E	0.841
10:133352326:C:A	H114Q	0.841
10:133352326:C:G	H114Q	0.841
10:133352407:G:C	E141D	0.827
10:133352407:G:T	E141D	0.827
10:133352399:G:A	G139R	0.825
10:133352399:G:C	G139R	0.825
10:133352313:A:C	D110A	0.824
10:133352412:A:G	D143G	0.817
10:133352324:C:G	H114D	0.805
10:133352312:G:C	D110H	0.795

dbSNP variants (sampled 300 via entrez): RS1000394913 (10:133350536 C>A), RS1000427476 (10:133350804 C>A,G,T), RS1001157769 (10:133345542 T>A), RS1001565324 (10:133350256 T>C), RS1001932617 (10:133349897 C>T), RS1003204110 (10:133348755 T>C), RS1003644616 (10:133348968 C>T), RS1005668422 (10:133348083 C>T), RS1005829653 (10:133353139 G>A,C), RS1006088770 (10:133347112 G>A), RS1006205892 (10:133352358 G>A,C), RS1007086286 (10:133346587 G>A,C,T), RS1007423177 (10:133352126 G>A,T), RS1007482678 (10:133346602 A>G), RS1007795975 (10:133351848 C>T)

Disease associations

OMIM: gene MIM:609776 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST007250_1	Nonunion in individuals with fractures	2.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0009707	fractures, ununited

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4879502 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 398 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL4098253	AZD2461	1	398

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

6 potent at pChembl≥5 of 6 total, top 6 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.16	IC50	6.87	nM	CHEMBL4854774
8.15	IC50	7.09	nM	AZD2461
8.08	IC50	8.35	nM	CHEMBL4850135
7.87	IC50	13.56	nM	CHEMBL4856941
7.82	IC50	15.28	nM	CHEMBL4869660
7.72	IC50	19.09	nM	CHEMBL4849327

PubChem BioAssay actives

6 with measured affinity, of 6 total; 6 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
3-acetamido-N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-5-[6-[4-[2-fluoro-5-[(4-oxo-3H-phthalazin-1-yl)methyl]benzoyl]piperazin-1-yl]-3-pyridinyl]-2-methylbenzamide	1773629: Inhibition of PRAP1 (unknown origin) by HT universal chemiluminescent assay	ic50	0.0069	uM
4-[[4-fluoro-3-(4-methoxypiperidine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one	1773629: Inhibition of PRAP1 (unknown origin) by HT universal chemiluminescent assay	ic50	0.0071	uM
N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-5-[6-[4-[2-fluoro-5-[(4-oxo-3H-phthalazin-1-yl)methyl]benzoyl]piperazin-1-yl]-3-pyridinyl]-2-methyl-3-(propanoylamino)benzamide	1773629: Inhibition of PRAP1 (unknown origin) by HT universal chemiluminescent assay	ic50	0.0083	uM
N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-[ethyl(propanoyl)amino]-5-[6-[4-[2-fluoro-5-[(4-oxo-3H-phthalazin-1-yl)methyl]benzoyl]piperazin-1-yl]-3-pyridinyl]-2-methylbenzamide	1773629: Inhibition of PRAP1 (unknown origin) by HT universal chemiluminescent assay	ic50	0.0136	uM
N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-5-[6-[4-[2-fluoro-5-[(4-oxo-3H-phthalazin-1-yl)methyl]benzoyl]piperazin-1-yl]-3-pyridinyl]-2-methyl-3-(3-methylbutanoylamino)benzamide	1773629: Inhibition of PRAP1 (unknown origin) by HT universal chemiluminescent assay	ic50	0.0153	uM
N-[(4,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-[ethyl(2-methylprop-2-enoyl)amino]-5-[6-[4-[2-fluoro-5-[(4-oxo-3H-phthalazin-1-yl)methyl]benzoyl]piperazin-1-yl]-3-pyridinyl]-2-methylbenzamide	1773629: Inhibition of PRAP1 (unknown origin) by HT universal chemiluminescent assay	ic50	0.0191	uM

CTD chemical–gene interactions

18 total (human), top 18 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, increases expression	4
Aflatoxin B1	affects expression, decreases expression, increases expression	3
sodium arsenite	decreases expression, increases expression, decreases reaction, increases secretion	2
Valproic Acid	affects expression, decreases expression	2
tris(2-butoxyethyl) phosphate	affects expression	1
2,4,5,2’,4’,5’-hexachlorobiphenyl	increases expression	1
CGP 52608	affects binding, increases reaction	1
bisphenol S	affects methylation, affects cotreatment, decreases methylation	1
jinfukang	affects cotreatment, increases expression	1
theaflavin-3,3’-digallate	affects expression	1
Resveratrol	affects cotreatment, decreases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Cisplatin	increases expression, affects cotreatment	1
Plant Extracts	affects cotreatment, decreases expression	1
Quercetin	increases expression	1
Tetrachlorodibenzodioxin	increases expression	1
Cyclosporine	decreases expression	1
Okadaic Acid	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4833010	Binding	Inhibition of PRAP1 (unknown origin) by HT universal chemiluminescent assay	Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA. — J Med Chem

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2C1	Abcam HeLa PRAP1 KO	Cancer cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.